Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. The firm operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The firm manufactures an inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. The respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.
Medical Developments International Limited 的關鍵財務報表是什麼?
根據最新的財務報表(Form-10K),Medical Developments International Limited 的總資產為 $66,淨損失為 $0
MDDVF 的關鍵財務比率是什麼?
Medical Developments International Limited 的流動比率為 6,淨利潤率為 0,每股銷售為 $0.34。
Medical Developments International Limited 的收入按細分市場或地理位置如何劃分?
Medical Developments International Limited 最大收入來源為 Pain Management,在最近的收益報告中收入為 21,296,000。就地區而言,Australia 是 Medical Developments International Limited 的主要市場,收入為 15,364,000。
Medical Developments International Limited 是否盈利?
無,根據最新的財務報表,Medical Developments International Limited 的淨損失為 $0
Medical Developments International Limited 有負債嗎?
是的,Medical Developments International Limited 的負債為 11
Medical Developments International Limited 的流通股有多少?
Medical Developments International Limited 的總流通股為 112.65